Briefs: Ipca Laboratories, Lupin and Zydus
News

Briefs: Ipca Laboratories, Lupin and Zydus

The company has extended its full co-operation and support to the officials of the Income Tax Department

  • By IPP Bureau | June 05, 2023

Income Tax Survey at Ipca Laboratories’ plants

The Income Tax Department has carried out survey proceedings at the company's offices in Mumbai and at Sikkim manufacturing plants between 30th May, 2023 to 3rd June, 2023.

The company has extended its full co-operation and support to the officials of the Income Tax Department during their survey proceedings and has provided timely and correct information/data asked for and shall continue to provide any further details/information that might be required by the department in future.

Lupin launches Darunavir Tablets in the United States

Lupin announced the launch of Darunavir Tablets, 600 mg and 800 mg, to market a generic equivalent of Prezista® Tablets of Janssen Products, LP. Darunavir Tablets, 600 mg and 800 mg (RLD Prezista) had estimated annual sales of USD 308 million in the U.S. (IQVIA MAT March 2023).

USFDA inspection at Zydus' animal health drug manufacturing facility at SEZ, Ahmedabad

Zydus Lifesciences announced that the group's animal health drug manufacturing facility at SEZ, Ahmedabad underwent a USFDA inspection from 30th May to 2nd June, 2023. The inspection closed with nil observations.

Upcoming E-conference

Other Related stories

Startup

Digitization